Tozasertib (VX-680, MK-0457)

For research use only. Not for use in humans.

目录号:S1048 中文名称:陶扎色替

Tozasertib (VX-680, MK-0457) Chemical Structure

CAS No. 639089-54-6

Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂,对Aurora A作用最强,无细胞试验中Kiapp为0.6 nM,而对Aurora B/Aurora C的作用较弱,对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3)c-ABL tyrosine kinase,也可被 Tozasertib 抑制,对应的Ki值分别为30 nM和20 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1098.34 现货
RMB 1211.51 现货
RMB 3017.92 现货
RMB 3833.09 现货
RMB 4316.13 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Tozasertib (VX-680, MK-0457)发表文献88篇:

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂,对Aurora A作用最强,无细胞试验中Kiapp为0.6 nM,而对Aurora B/Aurora C的作用较弱,对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3)c-ABL tyrosine kinase,也可被 Tozasertib 抑制,对应的Ki值分别为30 nM和20 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。
靶点
Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
体外研究

虽然VX-680具有多激酶特性,VX-680却诱导相似的细胞毒性,IC50约为300 nM,在G2/M期,核内复制期,及转染ABL或FLT-3激酶的BaF3细胞凋亡时,显示一个Aurora B 类似的抑制表现型。VX-680抑制CAL-62细胞增殖,这种作用存在时间依赖性。用VX-680处理14天,明显降低群体的数量和大小,处理8305C下降达到70%,处理CAL-62, 8505C,和BHT-101下降达到90%。用VX-680处理不同ATC细胞,抑制细胞增殖,IC50为25到150  nM,这种作用存在时间和剂量依赖性。在软琼脂中,VX-680明显削弱不同细胞系形成群落的能力。caspase-3的活性分析显示VX-680诱导不同细胞凋亡。VX-680处理CAL-62 细胞12小时,形成DNA含量≥4N细胞累积物。微速摄影分析显示VX-680处理的CAL-62细胞离开细胞中期。VX-680可以抑制组蛋白H3的磷酸化作用。[2] VX-680作用于携带T315I突变的BCR-Abl的病人样本,具有明显抑制活性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\xPIppUUN3ME2wMlAxOzN6IN88US=> NWjDXpBJW0GQR2LFVi=>
RS4-11 M{XNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTiTWM2OD1yLkCwOFA1KM7:TR?= M2\ZW3NCVkeURWK=
MFH-ino MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;vTWM2OD1yLkCwPVkh|ryP MW\TRW5IWkWU
NTERA-S-cl-D1 NF;MNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEG0N|Qh|ryP NUnRR4lZW0GQR2LFVi=>
697 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O4TWlEPTB;MD6wNlQ4OSEQvF2= M3;JcHNCVkeURWK=
NALM-6 M{\LWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvwUoJYUUN3ME2wMlAzPTV{IN88US=> NXLwTpZFW0GQR2LFVi=>
ES8 NFjtTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMES2NVMh|ryP M3rob3NCVkeURWK=
HUTU-80 NGDIPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEWyPVkh|ryP NVuyNnQyW0GQR2LFVi=>
MV-4-11 NES4epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGns[mpKSzVyPUCuNFc4QDJizszN MnfkV2FPT1KHUh?=
MONO-MAC-6 M2LsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n4fGlEPTB;MD6wO|g4QSEQvF2= NGrZVZpUSU6JUlXS
LC-2-ad NVf4[WNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfqZ4xKSzVyPUCuNFg4QDlizszN MWHTRW5IWkWU
BL-41 M{fh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P6NGlEPTB;MD6xNFQ1PSEQvF2= MoTaV2FPT1KHUh?=
A4-Fuk NFi1V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMUG1OlMh|ryP NFH6Z49USU6JUlXS
SW954 M3Hidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW2PFFKSzVyPUCuNVIzOjlizszN MWfTRW5IWkWU
BV-173 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[5XWlEPTB;MD6xNlY1OSEQvF2= M4PvUnNCVkeURWK=
TE-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfFTWM2OD1yLkG0PVgzKM7:TR?= NXLWTIJuW0GQR2LFVi=>
SK-UT-1 M{TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke2TWM2OD1yLkG1PVY2KM7:TR?= MVPTRW5IWkWU
SIG-M5 M{fBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrOeJpKSzVyPUCuNVY4ODdizszN MWPTRW5IWkWU
OCUB-M MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTCWmxRUUN3ME2wMlE3QTh|IN88US=> MnTnV2FPT1KHUh?=
K052 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\Ye2lEPTB;MD6xPVQ5KM7:TR?= NYjGZ2txW0GQR2LFVi=>
VA-ES-BJ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPGcphKSzVyPUCuNlAxQDZizszN MYDTRW5IWkWU
SW982 M3HJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWyTWM2OD1yLkKxN|gh|ryP MV7TRW5IWkWU
LB647-SCLC NX:0NXY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYraZpFVUUN3ME2wMlIyPTJ|IN88US=> MXLTRW5IWkWU
PSN1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfqTWM2OD1yLkKyNFI3KM7:TR?= MXXTRW5IWkWU
BB30-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKxOVhNUUN3ME2wMlIzPTlzIN88US=> MkfMV2FPT1KHUh?=
ST486 MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HyXGlEPTB;MD6yN|A5PyEQvF2= MXLTRW5IWkWU
MOLT-4 M4XjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3SHlqUUN3ME2wMlI{OzN5IN88US=> MWrTRW5IWkWU
EW-16 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW5WXFKSzVyPUCuNlM4PjhizszN MYXTRW5IWkWU
KS-1 NWS4bG9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HiO2lEPTB;MD6yN|c5PSEQvF2= NXLXeph6W0GQR2LFVi=>
SR MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXvTWM2OD1yLkK0OVY1KM7:TR?= M1ywOnNCVkeURWK=
KM12 NVzEcJFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOPJJ5UUN3ME2wMlI3OzZizszN MlfEV2FPT1KHUh?=
EM-2 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTsUJpwUUN3ME2wMlI3PjRzIN88US=> MX3TRW5IWkWU
MEG-01 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD5SoJuUUN3ME2wMlI4QDR7IN88US=> NFH3ZWNUSU6JUlXS
NB13 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMke5PFQh|ryP NHrYOIlUSU6JUlXS
RKO NUHTXm42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwM{C4NVMh|ryP NXPteohlW0GQR2LFVi=>
CESS M{P1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwM{GzNlgh|ryP NYnTfohyW0GQR2LFVi=>
EoL-1-cell NVvmW|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\lXJJKSzVyPUCuN|M1PTlizszN M2\KVXNCVkeURWK=
DOHH-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwM{O3PFEh|ryP Mn:wV2FPT1KHUh?=
A388 NVj4RVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv1eHlKSzVyPUCuN|QxQDZizszN MUHTRW5IWkWU
LAMA-84 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS4XnRLUUN3ME2wMlM2OTd6IN88US=> NXniWYd7W0GQR2LFVi=>
IMR-5 NWPvVmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzQSIw6UUN3ME2wMlM2PTRizszN NGrJfpZUSU6JUlXS
KARPAS-422 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:zTVlJUUN3ME2wMlM4Ojd{IN88US=> NXfCTnh2W0GQR2LFVi=>
MRK-nu-1 NIXRd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwM{ixN{DPxE1? NYLYd2lNW0GQR2LFVi=>
BL-70 NE\3VXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwM{i5O|Qh|ryP NHPqVVVUSU6JUlXS
LXF-289 NWrTPZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Xn[GlEPTB;MD60NFQxPiEQvF2= M2rGVXNCVkeURWK=
RL95-2 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jkeGlEPTB;MD60NFU3PyEQvF2= MmHNV2FPT1KHUh?=
QIMR-WIL M3jhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrCTWM2OD1yLkSyOlc3KM7:TR?= MXHTRW5IWkWU
K-562 M2m3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXzVJU4UUN3ME2wMlQ{PDd{IN88US=> M{HRUnNCVkeURWK=
NCI-H510A MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknuTWM2OD1yLkSzPFI{KM7:TR?= NYjxTmVYW0GQR2LFVi=>
NCI-H524 NX7SR5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHu[GZKSzVyPUCuOVEyPDdizszN MYHTRW5IWkWU
KE-37 M2\WWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQ[IJLUUN3ME2wMlUzOTB{IN88US=> MYjTRW5IWkWU
KP-N-YS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\wblFIUUN3ME2wMlU1Ozl{IN88US=> NEGycXJUSU6JUlXS
LS-411N MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\LSodbUUN3ME2wMlU4PzV{IN88US=> MoeyV2FPT1KHUh?=
CTV-1 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwNUi3O|Mh|ryP M2XyfHNCVkeURWK=
NCI-SNU-16 M1u4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3hVIJSUUN3ME2wMlY{PTdzIN88US=> Mlm2V2FPT1KHUh?=
HT-144 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD1yLk[zO|k5KM7:TR?= NXu2V28xW0GQR2LFVi=>
NCI-H187 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PEdWlEPTB;MD62OFE{KM7:TR?= M2TSenNCVkeURWK=
OCI-AML2 M1XXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\i[29ZUUN3ME2wMlY1PDB|IN88US=> MnPkV2FPT1KHUh?=
CCRF-CEM NH7ISGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO2fYhKSzVyPUCuOlU{PDZizszN MnTOV2FPT1KHUh?=
ONS-76 M4foSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwNk[0OVgh|ryP MWDTRW5IWkWU
IST-SL2 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkNW9KSzVyPUCuO|E6QDJizszN MUfTRW5IWkWU
NB6 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwN{eyOVQh|ryP NUPMVVFkW0GQR2LFVi=>
SK-PN-DW MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7JS3RsUUN3ME2wMlc6OTRizszN MmS1V2FPT1KHUh?=
HCC1599 NIe4cFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\lZlV4UUN3ME2wMlgxQDd2IN88US=> MVfTRW5IWkWU
MC116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXSPHpKSzVyPUCuPFUxOTFizszN NUOyeZNyW0GQR2LFVi=>
TE-15 NWX3V49rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOEWwPVgh|ryP M3XNfnNCVkeURWK=
HOP-62 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwOE[zNlkh|ryP M3j1eHNCVkeURWK=
TGBC24TKB NGi5enFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jNNGlEPTB;MD64OlM5PSEQvF2= NYrvU3RGW0GQR2LFVi=>
HCE-4 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLlc29KSzVyPUCuPFgxPjNizszN NV:x[mR4W0GQR2LFVi=>
ALL-PO NYLyXJA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tp[mlEPTB;MD64PFE4PSEQvF2= M1;VPXNCVkeURWK=
KGN Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vDe2lEPTB;MD64PVk6PSEQvF2= MVrTRW5IWkWU
ML-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\VS4NKSzVyPUCuPVAzPTlizszN MVHTRW5IWkWU
ES4 M2nIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwOUGxNlgh|ryP NFSzUW9USU6JUlXS
SF126 NFrPS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrhTWM2OD1yLkm0PFE6KM7:TR?= MYLTRW5IWkWU
SK-N-DZ NIT4VmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3VWlEPTB;MD65OlE5QSEQvF2= NXvh[pZHW0GQR2LFVi=>
HCC1187 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPK[5BKSzVyPUGuNFA2ODVizszN NXXPOGxpW0GQR2LFVi=>
DU-4475 NFvKNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL5e445UUN3ME2xMlAyPzV4IN88US=> NHOw[oRUSU6JUlXS
NKM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr3OpVmUUN3ME2xMlAzPzd3IN88US=> NVjEU4dqW0GQR2LFVi=>
HL-60 NXzHbGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PHU2lEPTB;MT6wOlU4PCEQvF2= MV;TRW5IWkWU
SBC-1 M3zVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;WTWM2OD1zLkGyOVQzKM7:TR?= NXTvZ45qW0GQR2LFVi=>
TE-10 NXr3NYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;t[mlEPTB;MT6xNlk1PiEQvF2= MX7TRW5IWkWU
ETK-1 M4W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzZTWM2OD1zLkGzOlE{KM7:TR?= MXLTRW5IWkWU
HAL-01 NUnqV2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTKdo1KSzVyPUGuNVY4ODlizszN NXrsTld3W0GQR2LFVi=>
BB65-RCC MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XEc2lEPTB;MT6xPFAxPSEQvF2= NEW1UY1USU6JUlXS
EW-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHRNIdKSzVyPUGuNVg2PjJizszN NXvrfG1QW0GQR2LFVi=>
SK-NEP-1 NYXsS4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwMkGxNVEh|ryP MmXuV2FPT1KHUh?=
SK-LMS-1 NXzsfGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwMkKyNVIh|ryP MVTTRW5IWkWU
DEL MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnnVllCUUN3ME2xMlI2PjR|IN88US=> NUWxc|NsW0GQR2LFVi=>
GT3TKB NYXj[IJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwMkiwOVch|ryP M4f2fnNCVkeURWK=
MOLT-16 M4r4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof6TWM2OD1zLkO1OFA2KM7:TR?= NUDNUHNtW0GQR2LFVi=>
CMK M{nEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXQVFhKSzVyPUGuOFIyOTdizszN NXfuNHZ4W0GQR2LFVi=>
NB5 NHjnWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXXPYxKSzVyPUGuOlQzOjlizszN NX;1bXBQW0GQR2LFVi=>
NCI-H1963 M4\EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkKyTWM2OD1zLkewOVg{KM7:TR?= NHK0e3VUSU6JUlXS
KURAMOCHI MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxWXNKSzVyPUGuO|g6OTFizszN MU\TRW5IWkWU
TE-8 M1PwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwOECzOlgh|ryP NHPONI5USU6JUlXS
NCI-H1304 NW[0[nBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknnTWM2OD1zLkizNFc{KM7:TR?= MY\TRW5IWkWU
A101D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uyVWlEPTB;MT64O|M6PSEQvF2= MnS4V2FPT1KHUh?=
SCLC-21H M3TIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwOUewOVch|ryP NInsWZJUSU6JUlXS
GB-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLKVZRKSzVyPUKuNFE3PDdizszN M2SzZnNCVkeURWK=
KARPAS-45 NFP4Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PmRmlEPTB;Mj6wNlY2PCEQvF2= MUTTRW5IWkWU
ATN-1 NUfxd2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fRO2lEPTB;Mj6wNlg2QCEQvF2= MlS5V2FPT1KHUh?=
NCI-H720 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITVNppKSzVyPUKuNFYzPDRizszN NEnR[JhUSU6JUlXS
RPMI-6666 NXP2dnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXztNm9qUUN3ME2yMlE3OjB5IN88US=> NG\ucINUSU6JUlXS
NB17 NFvmelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL2TWM2OD1{LkK5Nlch|ryP NV64Wm0zW0GQR2LFVi=>
IST-SL1 NEP2T2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xTWM2OD1{LkK5O|Y2KM7:TR?= NUHLSmxnW0GQR2LFVi=>
SH-4 NE\qT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfIPYxNUUN3ME2yMlMzPDZ7IN88US=> MkP0V2FPT1KHUh?=
K5 NUS0dIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PHTGlEPTB;Mj60NFMyQSEQvF2= NWrLPG9iW0GQR2LFVi=>
OVCAR-4 M1K2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr4TWM2OD1{LkS2NVMh|ryP NHXsU3FUSU6JUlXS
ACN M3\kdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwNUCyNVMh|ryP MUXTRW5IWkWU
TGW NW\KNWY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTtTWM2OD1{Lk[1PFMzKM7:TR?= NI\keoFUSU6JUlXS
NCI-H2107 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD1{LkizO|EyKM7:TR?= MmiwV2FPT1KHUh?=
NCI-H82 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\TS2lEPTB;Mj64N|g{QCEQvF2= MlfyV2FPT1KHUh?=
SK-N-FI MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwOE[4Olgh|ryP NXHOTplZW0GQR2LFVi=>
LB1047-RCC NIXTVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwOEixNlYh|ryP M1nsRnNCVkeURWK=
LU-134-A M3Xn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonHTWM2OD1{Lki5NlYh|ryP NXHwc|A4W0GQR2LFVi=>
NCI-H209 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[zS4tKSzVyPUKuPVEzPTNizszN MnexV2FPT1KHUh?=
NOMO-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7teHhWUUN3ME2zMlAzOjd2IN88US=> MU\TRW5IWkWU
RH-1 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPBTWM2OD1|LkG3NlkyKM7:TR?= NGi2fmZUSU6JUlXS
LOUCY NXKyUpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jrTGlEPTB;Mz6xPFY6OyEQvF2= NVTtOY5TW0GQR2LFVi=>
TE-9 NE\oUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XkfmlEPTB;Mz6yOlc{PiEQvF2= MlHaV2FPT1KHUh?=
PF-382 NW\VSItkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XybWlEPTB;Mz6zOVc4QCEQvF2= MmLqV2FPT1KHUh?=
RPMI-8402 NVO0WFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36wUWlEPTB;Mz61PFYxOyEQvF2= NEi5XlJUSU6JUlXS
HEL Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2exRWlEPTB;Mz62N|Ih|ryP NXzMbJdTW0GQR2LFVi=>
NOS-1 M4fyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3nWWNKSzVyPUOuPFQ4PTRizszN M1u1WHNCVkeURWK=
ES1 NWLCN2xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHSUJVwUUN3ME2zMlkzOjl|IN88US=> MkTHV2FPT1KHUh?=
NCI-H2171 NVPrb4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD1|LkmyOFI{KM7:TR?= NXLQbIk2W0GQR2LFVi=>
NCI-H747 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfZTWM2OD1|Lkm0NlIyKM7:TR?= NH7QPFVUSU6JUlXS
MHH-NB-11 M3vwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HCU2lEPTB;Mz65OVMyOiEQvF2= MlO0V2FPT1KHUh?=
MZ1-PC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\YcodOUUN3ME2zMlk6OjRizszN NHXjfpFUSU6JUlXS
MMAC-SF M3rW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwMEK0Olch|ryP NGfTeplUSU6JUlXS
NMC-G1 NEnFWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzTUYxKSzVyPUSuNlI4OjNizszN MnvJV2FPT1KHUh?=
SW872 NHeyVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjs[pVtUUN3ME20MlM1OzRizszN MUXTRW5IWkWU
TE-12 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f6TGlEPTB;ND61OlM6PCEQvF2= M{jMd3NCVkeURWK=
LU-139 NUW5WmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTRwNkG4N|Uh|ryP MorTV2FPT1KHUh?=
HC-1 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nsfGlEPTB;ND62PVQ6PCEQvF2= M1T1V3NCVkeURWK=
COR-L279 NI\PTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrGUo9KSzVyPUSuO|U5QTFizszN M1;xdnNCVkeURWK=
SF268 NYHCZYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrYOmlKSzVyPUSuO|k6OTZizszN M135enNCVkeURWK=
MC-CAR NIHI[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\reHRXUUN3ME21MlA3PzV5IN88US=> NVvFSI82W0GQR2LFVi=>
TK10 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rX[mlEPTB;NT6zOVQ3QSEQvF2= Ml[zV2FPT1KHUh?=
TE-1 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LCXmlEPTB;NT60PVAxPCEQvF2= NUW2Xo9IW0GQR2LFVi=>
NCI-H2126 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVwNkS1O|Qh|ryP M{fpZ3NCVkeURWK=
Daudi MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j2eGlEPTB;NT62PVEzKM7:TR?= M4S4dnNCVkeURWK=
NCI-H1648 NFvkOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXNYFKSzVyPUWuPFE1PTRizszN NFvWenBUSU6JUlXS
OS-RC-2 NVixN5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jLbGlEPTB;NT65PFU6PyEQvF2= MVfTRW5IWkWU
DJM-1 M4PjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTZwM{S2OlYh|ryP MY\TRW5IWkWU
LS-1034 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1UFNKSzVyPU[uO|U3PiEQvF2= NXT3fmJsW0GQR2LFVi=>
NCI-H1581 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\XXWlEPTB;Nj63PFQxPSEQvF2= NI\NNJRUSU6JUlXS
UACC-257 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn5VHcxUUN3ME23MlA1PTF{IN88US=> Mo\BV2FPT1KHUh?=
KM-H2 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTdwMUi0OVch|ryP NV7yd|BOW0GQR2LFVi=>
NCI-H1436 NIntUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTdwNkm5N|Ih|ryP Ml;5V2FPT1KHUh?=
IA-LM MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7qcmNKSzVyPUeuPFU6KM7:TR?= M2THRXNCVkeURWK=
NCI-H526 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrSTlRKSzVyPUiuNlU3OzdizszN M133PXNCVkeURWK=
GCIY NYXKWJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:w[otKSzVyPUiuN|Y6PjVizszN MmHIV2FPT1KHUh?=
CP67-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvLWVcxUUN3ME24MlU{OjZizszN M1y2bHNCVkeURWK=
KALS-1 NV35bXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLkTWM2OD16LkizPFUyKM7:TR?= NX;LRlVOW0GQR2LFVi=>
NCI-H1770 M4DQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7MfVNKSzVyPUiuPVAzPjVizszN NF7kVnFUSU6JUlXS
8-MG-BA MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULkTmxIUUN3ME25MlMzQDR2IN88US=> MkHLV2FPT1KHUh?=
KY821 M4[1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTkR3pNUUN3ME25Mlc4PDh2IN88US=> MYnTRW5IWkWU
SNB75 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjEVIVKSzVyPUGwMlA4PiEQvF2= M4LqenNCVkeURWK=
NCCIT NX7rOVBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFzLkC1PFIh|ryP M3zrN3NCVkeURWK=
SJSA-1 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fPfGlEPTB;MUGuNlg6OSEQvF2= MXLTRW5IWkWU
LB373-MEL-D NIq1OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HvZ2lEPTB;MUGuN|gzPyEQvF2= MWrTRW5IWkWU
TALL-1 M{XSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFzLkSwOVgh|ryP MXPTRW5IWkWU
NB69 NWG5SJFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuweZdKSzVyPUGxMlc4ODVizszN M1iy[HNCVkeURWK=
NCI-H1355 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPsdpVKSzVyPUGxMlk1OjZizszN MWHTRW5IWkWU
DMS-153 NEjGU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W4WmlEPTB;MUKuNFQzPiEQvF2= MYLTRW5IWkWU
OPM-2 NF\qb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNTWM2OD1zMj6xOVk3KM7:TR?= NHLQVoxUSU6JUlXS
NB1 NUX3SmVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTyWpFiUUN3ME2xNk4zQSEQvF2= Mm\6V2FPT1KHUh?=
A3-KAW NYXXeVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTVRY1tUUN3ME2xNk4{OjN4IN88US=> NV3RWWs6W0GQR2LFVi=>
NCI-H1882 NYfUSVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz1foJPUUN3ME2xNk41ODZ4IN88US=> MojnV2FPT1KHUh?=
KG-1 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfHWlNKSzVyPUGyMlY2PDVizszN MYXTRW5IWkWU
LC4-1 M33XSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRU2lEPTB;MUKuO|cxPiEQvF2= M4L5SnNCVkeURWK=
HCE-T NUi2e|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD1zMz6wNFQ6KM7:TR?= MX3TRW5IWkWU
NEC8 M1Wwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjlTWM2OD1zMz6xNFM5KM7:TR?= NULOb2ZGW0GQR2LFVi=>
IST-MEL1 M2ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnuSIxDUUN3ME2xN{42Pzh6IN88US=> NHrv[HpUSU6JUlXS
EW-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi3fplKSzVyPUGzMlc1ODJizszN NWjUeVdrW0GQR2LFVi=>
CTB-1 M161[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe1fHpKSzVyPUG0MlA{OjlizszN MXXTRW5IWkWU
LS-123 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXXV5RKSzVyPUG0MlE2QDhizszN NUPzcWFQW0GQR2LFVi=>
NCI-H1417 M{Dtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnybHhSUUN3ME2xOE4{ODV{IN88US=> NFXmeo9USU6JUlXS
MZ7-mel M{DjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjkTndKSzVyPUG0MlQ1OzNizszN MkfiV2FPT1KHUh?=
JiyoyeP-2003 M1XxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrpdoc5UUN3ME2xOU43OzJ4IN88US=> M1fSbHNCVkeURWK=
ES6 M{DDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjH[2pUUUN3ME2xOk4zOzZzIN88US=> NGq2XIxUSU6JUlXS
HH NX33cIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;4TWM2OD1zNz6xPVY{KM7:TR?= NFPDco1USU6JUlXS
SF539 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5Lkm5NlIh|ryP MXjTRW5IWkWU
Calu-6 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnpTY9{UUN3ME2xPU4zOzlizszN NFLRPXlUSU6JUlXS
SK-MM-2 NEfzN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrFVW9KSzVyPUG5MlU2PSEQvF2= NF7veIlUSU6JUlXS
IST-MES1 M{TOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF7Lk[2OlMh|ryP M4fXUnNCVkeURWK=
GI-ME-N MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzrTWM2OD1zOT64NlI4KM7:TR?= M2PZU3NCVkeURWK=
CAL-148 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDmcGdKUUN3ME2yNE46QTN2IN88US=> M1:1fXNCVkeURWK=
EVSA-T NUDOPGlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TUXWlEPTB;MkGuNVQ6QSEQvF2= NEi4SXlUSU6JUlXS
LP-1 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDVTWM2OD1{MT6zOFMzKM7:TR?= MWDTRW5IWkWU
BOKU MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjBTWM2OD1{MT60OVM{KM7:TR?= MmP6V2FPT1KHUh?=
KLE NWXLS2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLjTWM2OD1{Mj6xPVA{KM7:TR?= Ml\RV2FPT1KHUh?=
LB831-BLC MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPZ[GZJUUN3ME2yOU4yPTJ4IN88US=> M{jkR3NCVkeURWK=
NCI-H889 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nEdmlEPTB;MkWuNVk{OSEQvF2= MUnTRW5IWkWU
REH NXO5Nld5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof4TWM2OD1{NT60OlcyKM7:TR?= Mor2V2FPT1KHUh?=
KP-N-RT-BM-1 MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M322V2lEPTB;MkWuOFc2OiEQvF2= M1qwUHNCVkeURWK=
MPP-89 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G2VGlEPTB;MkWuOVMyPCEQvF2= M3n2PHNCVkeURWK=
no-11 M2PmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m3T2lEPTB;MkWuO|Q4KM7:TR?= M4LYVnNCVkeURWK=
NCI-H748 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT6fJJKSzVyPUK1Mlc3OjdizszN NHX2S49USU6JUlXS
LB2518-MEL NInmbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DsZmlEPTB;MkeuNVc4OyEQvF2= MonEV2FPT1KHUh?=
TGBC1TKB NHjHS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHUTWM2OD1{Nz61OVg2KM7:TR?= MmL2V2FPT1KHUh?=
MHH-PREB-1 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ixPGlEPTB;MkiuNFc{PCEQvF2= M3Hhe3NCVkeURWK=
MZ2-MEL NV7QV285T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpTmlEPTB;MkiuOlE1OyEQvF2= M4HVWHNCVkeURWK=
U-266 NWjtSJU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ6Lk[zOlYh|ryP NHP2NGdUSU6JUlXS
SNU-C1 M1TVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD1{OD65OFMh|ryP NXLxXllqW0GQR2LFVi=>
SW962 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XMUWlEPTB;M{CuNlc1PyEQvF2= MVXTRW5IWkWU
Raji M{TIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\qSVdKSzVyPUOwMlU2QTJizszN M1jQZXNCVkeURWK=
KNS-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInTVlBKSzVyPUOwMlg6PTZizszN NGXuXXNUSU6JUlXS
LB996-RCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fOfWlEPTB;M{GuNVcxOiEQvF2= MoqwV2FPT1KHUh?=
CHP-126 NV31NGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm1TWM2OD1|MT6xPVg1KM7:TR?= M{XlOHNCVkeURWK=
RXF393 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXJTWM2OD1|Mj60PVch|ryP NGjBOnZUSU6JUlXS
COLO-684 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfGVpBIUUN3ME2zNk43PDN6IN88US=> MXLTRW5IWkWU
A704 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0S2RKSzVyPUOzMlU2OzhizszN MYTTRW5IWkWU
A253 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\rfo83UUN3ME2zN{42QDV{IN88US=> MkPTV2FPT1KHUh?=
KNS-81-FD NFHiZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HlfmlEPTB;M{SuOVQ2PiEQvF2= NWruT|RLW0GQR2LFVi=>
TE-441-T M1z5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfYTWM2OD1|ND62N|cyKM7:TR?= NYPEWlhOW0GQR2LFVi=>
HCC2157 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;CeWlEPTB;M{WuOFYyQSEQvF2= MVvTRW5IWkWU
ES3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTN4Lk[3OUDPxE1? MUDTRW5IWkWU
NCI-H1155 NUHWb5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW5cZN[UUN3ME2zO{45OTVizszN MXHTRW5IWkWU
SNU-C2B NV\k[2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXreGIzUUN3ME2zPE4yPjV2IN88US=> M{P4NHNCVkeURWK=
JAR NHPSU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVeyOJBnUUN3ME2zPE4zPDR7IN88US=> Mn7IV2FPT1KHUh?=
GDM-1 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN6LkmxNVYh|ryP M4HkTXNCVkeURWK=
KU812 NGnnV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfyUmdKSzVyPUSxMlUxPyEQvF2= MYfTRW5IWkWU
BC-1 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PJZmlEPTB;NEKuOlc{OSEQvF2= M{fMfnNCVkeURWK=
GI-1 NXjXVIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LqTGlEPTB;NEKuPVE6OiEQvF2= Ml;VV2FPT1KHUh?=
NCI-H1694 NFzvOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDTWM2OD12ND65OFczKM7:TR?= M2\zSXNCVkeURWK=
DG-75 NX7sZoZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLxTWM2OD12NT6xOVc4KM7:TR?= NX61PZd1W0GQR2LFVi=>
COR-L88 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Le2lEPTB;NEWuNlc4QCEQvF2= NIr5W3lUSU6JUlXS
LS-513 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml36TWM2OD12NT65NVU3KM7:TR?= M13jcXNCVkeURWK=
HD-MY-Z M2XpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR4LkS2NVIh|ryP MnrGV2FPT1KHUh?=
L-363 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S1OWlEPTB;NE[uPFgyKM7:TR?= Mn7rV2FPT1KHUh?=
TE-6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TRbGlEPTB;NEiuOFQ3KM7:TR?= M{\pXnNCVkeURWK=
NCI-H345 NWHJVVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHHTWM2OD12OD60Olgh|ryP NYnUeY1ZW0GQR2LFVi=>
TE-5 NVjG[5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y4RWlEPTB;NEmuO|EyQCEQvF2= M1j5WXNCVkeURWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DLK / p-MKK7 / MKK7 / p-JNK / JNK ; 

PubMed: 23431148     


Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. 

p-AURKA / AURKA / Survivin ; 

PubMed: 28218735     


BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. 

YAP; 

PubMed: 31160567     


Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. 

p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 21600017     


NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.

23431148 28218735 31160567 21600017
Immunofluorescence
α-tubulin / Aurora-A ; 

PubMed: 21600017     


The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.

21600017
Growth inhibition assay
Cell viability; 

PubMed: 21600017     


VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, *p < 0.05, **p < 0.01, compared to control.

21600017
体内研究 VX-680作用于人类AML(HL-60)移植瘤模型明显降低肿瘤尺寸。VX-680按75 mg/kg剂量给药实验鼠,每天腹腔注射两次,持续13天,与对照组相比,平均肿瘤体积下降达98%。肿瘤体积比实验之前初始体积小很多。按12.5 mg/kg剂量每天给药两次,肿瘤生长也明显降低,这种作用存在剂量依赖性。VX-680耐受性很好,只有在使用高剂量时可以观察到实验动物体重稍微降低。通过比较cisplatin,按5.4 mg/kg剂量给药,每四天腹腔注射一次,一共进行三次,抑制肿瘤生长只达9%。VX-680作用于胰脏和结肠移植瘤,也引起肿瘤衰退。VX-680静脉注射给药携带HCT116肿瘤的实验鼠,显示很强的抗癌活性。使用高剂量VX-680(每小时2 mg/kg)处理,明显提高效果,比实验钱的初始肿瘤平均尺寸下降56%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[3]

- 合并

激酶抑制实验:

丙酮酸激酶/乳酸脱氢酶催化NADH的氧化,伴随着ATP的消耗,观察340 nm 处吸光值的降低。反应包括100 mM Tris (pH 为 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM磷酸烯醇丙酮酸, 0.6 mg/ml NADH, 75 ml丙酮酸激酶, 105 ml 乳酸脱氢酶,和0.5 mM 基底肽(序列为EAIYAAPFAKKK)。加入足够的激酶开始反应,反应的激酶浓度达到30 nM,用微量滴定板分光光度计在30oC进行30分钟,观察吸收率的降低。通过加入3.75 μl 溶于100% DMSO的VX-680 或单独DMSO,获得抑制常数。按如下公式计算Ki值,Ki = IC50/(1+[S]/Kd),[S]=[ATP]=2.2 mM, Kd=70 μM。假定作用于野生型和H396P Abl 激酶域的Kd(ATP)为70 μM,计算以上各值。
细胞实验:

[2]

- 合并
  • Cell lines: CAL-62细胞
  • Concentrations: 5-500 nM
  • Incubation Time: 4天
  • Method:

    对照组CAL-62细胞培养在二甲亚砜和DMSO中,实验组加入500 nM VX-680,处理1到5天。加入不同浓度(5到500 nM) Aurora抑制剂处理不同ATC细胞4天,用来测定VX-680作用于细胞增殖的剂量依赖性。细胞在温育结束前加30 mM BrdU标记,脉冲2小时。通过比色免疫分析使用细胞增殖ELISA试剂盒分析BrdU的合并率。通过比较VX-680处理的细胞和对照组细胞得到结果,


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 右侧腋窝处皮下注射107 HL-60白血病细胞的雌性无胸腺NCr-nu鼠
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.59
化学式

C23H28N8OS

CAS号 639089-54-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457)供应商 | 采购Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457)价格 | Tozasertib (VX-680, MK-0457)生产 | 订购Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID